CMC & manufacturing support for biotech developing a novel small molecule
Challenge
A biotech company was developing its first oral compound — a novel small molecule. The company needed support in taking the compound to first-in-man studies and Phase II clinical trials.
Solution
Our CMC consultant joined the project team responsible for the drug's development, providing guidance and hands-on support in several key areas:
- drug substance characterization, including polymorphism and salt selection studies, development of analytical methods and stability testing
- pre-formulation studies as part of dosage form selection
- designing and developing a formulation for Phase I studies, which could be readily modified for Phase II trials
- selecting and managing chief research officers and chief marketing officers responsible for CMC activities
- providing input into the specifications for drug substance and product
- compiling CMC data for the IMPD (Investigational Medicinal Product Dossier)
Product Development Services
Our expert teams are ready to support you through every step of the pharmaceutical product development process, leveraging our scientific, clinical and commercial expertise to help you maximize value at each stage.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Gene therapy preclinical, CMC, and regulatory strategy
Challenge: An early-stage biotechnology startup company reached out to Alacrita for critical support of its two lead AAV-delivered gene therapy programs. As a virtual company, the...
Interim chief medical officer for antiviral drug company
Challenge A European company developing novel antiviral drugs urgently needed an experienced pharmaceutical physician to work as an interim CMO, as the predecessor was about to...
Identiying molecules for novel formulation technology
Challenge A company had developed a technology for overcoming solubility issues in drug formulations and was planning to develop a small number of 505 (b)(2) candidate molecules....
Indication selection assessment for clinical stage oncology small molecule
Challenge: A venture capital firm was interested in an independent indication selection strategic assessment of a clinical stage small molecule oncology asset they had invested...
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.